Agios Pharmaceuticals | Los Gastos De Explotación



Operating Expenses Cambio Fecha
AbbVie USD 9.61B 6.98B 2025-03
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Amgen USD 6.78B 401M 2024-12
Arrowhead Research USD 163.91M 1.71M 2024-12
Astellas Pharma JPY 395.77B 237.82B 2025-03
AstraZeneca USD 9.91B 2.94B 2025-03
Bayer EUR 8.2B 5.59B 2024-12
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Daiichi Sankyo JPY 435.08B 11.65B 2025-03
Eli Lilly USD 7.32B 1.06B 2025-03
Exelixis USD 403.55M 82K 2025-01
Gilead Sciences USD 4.43B 687M 2025-03
GlaxoSmithKline GBP 5.3B 2.12B 2025-03
Incyte USD 847.73M 29.46M 2025-03
Ionis Pharmaceuticals USD 278M 59.4M 2025-03
Merck USD 9.66B 1.67B 2025-03
Moderna USD 1.16B 1.06B 2025-03
Novartis USD 11.28B 1.73B 2024-12
Novartis USD 10.15B 579M 2024-12
Pfizer USD 10.05B 8.12B 2025-03
Regeneron Pharmaceuticals USD 2.44B 362M 2025-03
Roche Holding CHF 11.43B 1.48B 2024-12
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Agios Pharmaceuticals Los Gastos De Explotación - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.